2025 MaTOS Lung | Session I | Smoking Cessation, Lung Cancer Screening and Molecular Diagnosis
Overview
Dr. Krishnan-Sarin reviewed e-cigarettes, noting potential cessation benefits but risks of addiction, youth uptake, and cancer effects, urging FDA-approved cessation and tighter regulation.
Dr. Antonoff highlighted gaps in lung cancer screening, low-dose CT benefits, poor uptake, policy barriers, and need for AI and risk models to improve access and equity.
Dr. Silvestri reviewed incidental lung nodules, stressing early detection, rising localized diagnoses, risks of overevaluation, and benefits of dedicated nodule clinics.
Dr. Rivera highlighted biomarker use to assess lung nodule cancer risk, showing high accuracy and reduced unnecessary procedures through genomic classifiers.
The Q & A session highlighted lung cancer screening advances, stressing nodule clinics, AI, biomarkers, radiomics, non-smoker risk, radiation concerns, and avoiding over-treatment.
Dr. Antonoff highlighted gaps in lung cancer screening, low-dose CT benefits, poor uptake, policy barriers, and need for AI and risk models to improve access and equity.
Dr. Silvestri reviewed incidental lung nodules, stressing early detection, rising localized diagnoses, risks of overevaluation, and benefits of dedicated nodule clinics.
Dr. Rivera highlighted biomarker use to assess lung nodule cancer risk, showing high accuracy and reduced unnecessary procedures through genomic classifiers.
The Q & A session highlighted lung cancer screening advances, stressing nodule clinics, AI, biomarkers, radiomics, non-smoker risk, radiation concerns, and avoiding over-treatment.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Luis E. Raez, MD
Suchitra Krishnan-Sarin, PhD
Mara B. Antonoff, MD
Gerard A. Silvestri, MD, MS
M. Patricia Rivera, MD
Date of Release
January 7th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)